Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Latest

    Pandemic's long-term effects fuel debate

    By ZHANG ZHIHAO | China Daily | Updated: 2020-07-31 07:02
    Share
    Share - WeChat
    A medical staff member is seen next to a patient suffering from the coronavirus disease (COVID-19) in the intensive care unit at the Circolo hospital in Varese, Italy, April 9, 2020. [Photo/Agencies]

    Double-edged sword

    Yi Fan, a doctor from Wuhan, contracted the virus, which left his skin darkened, while treating patients at the start of the outbreak. He has been known fondly by netizens as the "dark-faced angel", although recent photos show that his skin color has much improved.

    For his peers, Yi's case serves as a reminder that COVID-19 requires scrupulous care.

    During a media briefing in May, Duan Jun, a senior intensive care physician at the China-Japan Friendship Hospital in Beijing, said the skin darkening was due to a combination of the antifungal drug Polymyxin B and liver damage, which caused iron to build up in the blood.

    Mao Yonghui, a senior nephrologist at Beijing Hospital who treated severe cases of COVID-19 in Wuhan, said medical workers must take the adverse effects of medication into account, as many of the powerful drugs being used can damage the liver, kidneys and gastrointestinal system.

    "Most of the drugs' side effects can be mitigated through careful use and meticulous monitoring," she said. "The long-term consequences of the virus are puzzling enough, so the last thing we want is for the treatment to have any long-lasting effects."

    According to the World Health Organization, no effective drugs are currently available to combat COVID-19. However, some potential candidates have recently received a considerable amount of hype and endorsement from the media and politicians. These drugs include the experimental antiviral remdesivir and dexamethasone, a steroid.

    The journal Science reported that the US government recently stockpiled enough supplies of remdesivir for three months. The UK and Japan have made dexamethasone part of the care for patients in critical condition after a preliminary study found that the steroid could reduce mortality by about one-third for those on ventilators, the report said.

    However, Mao said an apparent lack of reporting on the adverse effects of the drugs, which can pose long-term health risks if not taken properly, remains a concern.

    "The more encouraging a candidate drug is, the more careful doctors and public health officials should be when giving it to the public," she said. "But we know such rationality is in short supply, especially during a pandemic."

    The adverse effects of remdesivir in treating COVID-19 remain unclear, as the drug is still being developed. However, evidence of risk to the liver and kidneys has been reported and is under intense scientific scrutiny, according to studies published in The Lancet and New England Journal of Medicine.

    A Beijing orthopedist, speaking on condition of anonymity, said he was deeply concerned when the UK and Japan rushed to approve dexamethasone as a standard treatment for critically ill COVID-19 patients, based on early evidence.

    "Dexamethasone, prednisone and methylprednisolone were among the corticosteroids (steroid hormones produced in the adrenal cortex or made synthetically) widely used by doctors during the SARS epidemic. High-dosage patients experienced bone tissue death, diabetes, psychosis and other chronic conditions," he said.

    In January, a clinical guideline released by the WHO advised against the routine administering of corticosteroids to treat viral pneumonia and ARDS-two conditions caused by COVID-19. The advice was based on studies of the drugs' long-term side effects on SARS patients. However, the guideline also stressed that studies had notable design flaws and should be treated with a degree of skepticism.

    The Beijing orthopedist said: "I believe that when pulling critically ill patients away from death's door, all options should be on the table, including dexamethasone, which is a cheap and accessible drug. The key is administering it with extreme care and caution."

    In China, the national guideline on COVID-19 care states that patients can receive three to five days of treatment with corticosteroids based on their symptoms, but the daily dosage cannot exceed 1 milligram to 2 milligrams per kilogram of body weight. Meanwhile, the immunosuppressive effect and delayed viral clearance-the time in which a virus can no longer be detected in blood tests-caused by the steroids must be accounted for.

    In an open letter published in The Lancet in late February, five Chinese doctors said the benefits and harm caused by using corticosteroids must be considered carefully. Dosage should be low-to-moderate, and the duration must be less than seven days.

    |<< Previous 1 2 3 4 Next   >>|
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    中文字幕无码AV波多野吉衣| 色欲狠狠躁天天躁无码中文字幕 | 久久精品无码专区免费 | 日韩精品无码免费专区午夜不卡 | 免费无码一区二区| 伊人久久综合精品无码AV专区| 亚洲精品人成无码中文毛片| 少妇人妻无码专区视频| 人妻AV中出无码内射| 精品久久无码中文字幕| 亚洲Av无码专区国产乱码不卡| 免费无码又爽又刺激高潮视频| 中文字幕一区二区三区在线不卡| 久久亚洲精精品中文字幕| 亚洲成?v人片天堂网无码| 波多野结AV衣东京热无码专区| 亚洲AV无码专区国产乱码电影| 区三区激情福利综合中文字幕在线一区| 最近中文字幕大全免费版在线| 97无码免费人妻超级碰碰夜夜| 亚洲av无码国产精品色午夜字幕 | 无码专区中文字幕无码| 成人午夜福利免费无码视频| 久久亚洲中文字幕精品一区| 99久久中文字幕| 日韩欧美一区二区不卡中文| 日韩av无码中文字幕| 色综合久久无码中文字幕| 中文字幕亚洲乱码熟女一区二区| 亚洲精品国产日韩无码AV永久免费网 | 无码超乳爆乳中文字幕久久| 中文精品无码中文字幕无码专区| 高清无码午夜福利在线观看| 婷婷四虎东京热无码群交双飞视频| 久久久久综合中文字幕| 高清无码v视频日本www| 超清无码无卡中文字幕| 亚洲av无码片在线播放| 秋霞鲁丝片Av无码少妇| 91久久九九无码成人网站| 亚洲精品国产日韩无码AV永久免费网 |